Cowen’s 43rd Annual Healthcare Conference
Tuesday, March 07, 2023 1:30 PM EST
Q4 2022 Ocular Therapeutix, Inc. Earnings Conference Call
Monday, March 06, 2023 4:30 PM EST
Ocular Therapeutix Interim 10-month Data Update from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
Monday, February 13, 2023 8:30 AM EST

Corporate Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery and the treatment of ocular itching associated with allergic conjunctivitis...

Data Provided by Refinitiv. Minimum 15 minutes delayed.